Research advances in proton pump inhibitor and complications of liver cirrhosis
DOI:10.3969/j.issn.1001-5256.2020.11.036
- VernacularTitle:质子泵抑制剂与肝硬化并发症的研究进展
- Author:
Linxiang LIU
1
;
Yuan NIE
;
Xuan ZHU
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital of Nanchang University & Jiangxi Institute of Digestive Diseases, Nanchang 330006, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis;
proton pump inhibitors;
gastrointestinal hemorrhage;
peritonitis;
hepatic encephalopathy;
carcinoma, hepatocellular;
gastrointestinal microbiome
- From:
Journal of Clinical Hepatology
2020;36(11):2557-2560
- CountryChina
- Language:Chinese
-
Abstract:
Proton pump inhibitor (PPI) is often used for the prevention and treatment of digestive system diseases, and the adverse outcomes caused by the use of PPI are increasingly concerned by scholars. This article elaborates on the association of the complications of liver cirrhosis, such as upper gastrointestinal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatocellular carcinoma, and infection, and the change in gut microbiota with the use of PPI, and points out that in clinical practice, it is important to master the medication rules of PPI, understand the risk of complications caused by PPI, and actively improve the complications caused by medication.
